A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 15 Jan 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Jun 2025.
- 16 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Dec 2024.